Skip to main content

Adenoid Cystic Carcinoma clinical trials at UC Cancer

2 research studies open to eligible people

Showing trials for
  • A Study of the Drug ONC-392 in Advanced Solid Tumors and Lung Cancer

    open to eligible people ages 18 years and up

    This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.

    at UC Davis

  • Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial

    open to eligible people ages 18 years and up

    The aim of this study is to learn whether the early initiation of a specialized and focused type of radiation called stereotactic body radiation therapy (SBRT) will impact the progression of advanced adenoid cystic carcinoma, quality of life, and overall survival. The name(s) of the study intervention involved in this study is: - Stereotactic Body Radiation Therapy (SBRT)

    at UCSF

Our lead scientists for Adenoid Cystic Carcinoma research studies include .